Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 11/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 4/20 | 0.55 |
| ▸ | TGM2 | P21980 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.48 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29711265 | 0.74 | CES1 (0.59) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL2259762 | 0.74 | CES1 (0.59) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL31492057 | 0.73 | CES1 (0.57) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL3845335 | 0.73 | CES1 (0.57) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL31634050 | 0.73 | CES1 (0.57) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL17818354 | 0.73 | CES1 (0.57) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL126628 | 0.73 | CES1 (1.00) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL18930798 | 0.73 | CES1 (0.57) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL995401 | 0.73 | CES1 (1.00) | CES1TTRBCHETGM2ALDH1A1 | |
| SCHEMBL1749687 | 0.73 | CES1 (0.57) | CES1TTRBCHETGM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106167461-A | A kind of new type water-solubility Isatine derivatives and preparation method and application | 天津科技大学 | 2016-11-30 | — | — | CN | disclosed |
| CN-105175308-A | Isatin derivative 3-(4-nitrophenylimino)indol-2-one, preparation method thereof, and application thereof in preparation of antidepressants | UNIV ZHEJIANG OCEAN | 2015-12-23 | — | — | CN | disclosed |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | disclosed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | CASP5, SLC1A5, CTSZ | CES1 252/4885TTR 3503/4885BCHE 184/4885 |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | CES1 174/4885TTR 3659/4885BCHE 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.